Table 2.

Predicted probabilities and rankings of repurposing candidate drugs in phase 3 clinical trial for Alzheimer’s disease in 2021

Models	Brexpiprazole	Caffeine	Escitalopram	Guanfacine	Hydralazine	Metformin	Omega-3-carboxylic acids	Median
DREAMwalk	0.736 (210)	0.910 (59)	0.875 (82)	0.602 (326)	0.481 (412)	0.03 (1440)	0.342 (564)	0.602 (326)
edge2vec	0.499 (1496)	0.582 (975)	0.616 (738)	0.584 (962)	0.626 (665)	0.531 (1362)	0.592 (912)	0.584 (962)
ComplEx	0.466 (886)	0.680 (49)	0.412 (1180)	0.503 (698)	0.678 (51)	0.531 (549)	0.409 (1199)	0.503 (698)
DTi2vec	0.769 (211)	0.706 (238)	0.870 (104)	0.11 (970)	0.11 (968)	0.047 (1346)	0.443 (456)	0.443 (456)
node2vec	0.338 (1631)	0.556 (204)	0.439 (982)	0.477 (606)	0.508 (366)	0.350 (1618)	0.404 (1327)	0.439 (982)
NEWMIN	0.692 (120)	0.576 (273)	0.596 (248)	0.431 (617)	0.391 (925)	0.380 (1037)	0.436 (589)	0.436 (589)
WalkPool	0.237 (1471)	0.62 (179)	0.227 (1538)	0.239 (1458)	0.436 (514)	0.386 (747)	0.509 (292)	0.386 (747)
SEAL	0.338 (1085)	0.518 (247)	0.426 (699)	0.281 (1396)	0.337 (1086)	0.341 (1071)	0.363 (980)	0.341 (1071)

For each model, the drug-disease association probabilities were measured for ten times, then ranked by their average probabilities. The ranks of the drugs are shown in parentheses, and the highest probability and rank for each drug are highlighted in bold.